The company describes OEA as a newly discovered lipid mediator involved in the regulation of feeding.
Chemi Nutra (White Bear Lake, MN) will showcase PhosphoLean NOPE+EGCG, a novel, proprietary hunger-control ingredient whose mechanism of action involves oleoyl ethanolamide (OEA). The company describes OEA as a newly discovered lipid mediator involved in the regulation of feeding, and a natural compound responsible for signaling the brain to stop hunger sensations. “Thus,” the company says, “PhosphoLean NOPE+EGCG shuts down hunger, stops binge eating and diet stress, and reduces food intake-leading to long-term diet success and successful weight loss.” It says PhosphoLean NOPE+EGCG has been clinically proven to help dieters.
Chemi Nutra, Booth 630
Judge in CRN’s complaint against NY denies the State’s motion to dismiss
Published: May 14th 2024 | Updated: May 15th 2024New York State's motion to dismiss CRN's lawsuit against the law banning the sale of weight management and muscle-building supplements to minors has been partially denied, allowing CRN to proceed with its First Amendment Claim.
Judge denies CRN’s motion for preliminary injunction but its lawsuit against NY state will proceed
April 23rd 2024The judge in CRN's lawsuit against NY state's law banning the sale of weight management and muscle building supplements to minors has denied its motion for a preliminary injunction, but determined that CRN has standing to sue on behalf of its members.
CRN NY State lawsuit update: Dispatch from SupplySide East 2024
April 18th 2024CRN's Steve Mister updates Nutritional Outlook about its ongoing litigation against NY State. The organization sued the state to prevent the enforcement of law that bans sale of weight management supplements to minors.